BCYC vs. TYRA, ARQT, OCUL, LQDA, SAVA, INVA, CNTA, OPK, ETNB, and IRWD
Should you be buying Bicycle Therapeutics stock or one of its competitors? The main competitors of Bicycle Therapeutics include Tyra Biosciences (TYRA), Arcutis Biotherapeutics (ARQT), Ocular Therapeutix (OCUL), Liquidia (LQDA), Cassava Sciences (SAVA), Innoviva (INVA), Centessa Pharmaceuticals (CNTA), OPKO Health (OPK), 89bio (ETNB), and Ironwood Pharmaceuticals (IRWD). These companies are all part of the "pharmaceutical preparations" industry.
Bicycle Therapeutics (NASDAQ:BCYC) and Tyra Biosciences (NASDAQ:TYRA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, dividends, earnings, institutional ownership, risk, community ranking, profitability, valuation and analyst recommendations.
Bicycle Therapeutics has a beta of 0.9, meaning that its stock price is 10% less volatile than the S&P 500. Comparatively, Tyra Biosciences has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500.
86.2% of Bicycle Therapeutics shares are owned by institutional investors. Comparatively, 84.1% of Tyra Biosciences shares are owned by institutional investors. 8.5% of Bicycle Therapeutics shares are owned by company insiders. Comparatively, 15.4% of Tyra Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Tyra Biosciences has a net margin of 0.00% compared to Bicycle Therapeutics' net margin of -404.14%. Tyra Biosciences' return on equity of -28.61% beat Bicycle Therapeutics' return on equity.
Bicycle Therapeutics presently has a consensus price target of $46.86, indicating a potential upside of 120.50%. Tyra Biosciences has a consensus price target of $23.50, indicating a potential upside of 30.19%. Given Bicycle Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Bicycle Therapeutics is more favorable than Tyra Biosciences.
Tyra Biosciences has lower revenue, but higher earnings than Bicycle Therapeutics. Tyra Biosciences is trading at a lower price-to-earnings ratio than Bicycle Therapeutics, indicating that it is currently the more affordable of the two stocks.
Bicycle Therapeutics received 102 more outperform votes than Tyra Biosciences when rated by MarketBeat users. Likewise, 68.57% of users gave Bicycle Therapeutics an outperform vote while only 62.07% of users gave Tyra Biosciences an outperform vote.
In the previous week, Bicycle Therapeutics and Bicycle Therapeutics both had 8 articles in the media. Bicycle Therapeutics' average media sentiment score of 0.74 beat Tyra Biosciences' score of 0.64 indicating that Bicycle Therapeutics is being referred to more favorably in the media.
Summary
Bicycle Therapeutics beats Tyra Biosciences on 9 of the 16 factors compared between the two stocks.
Get Bicycle Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BCYC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BCYC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bicycle Therapeutics Competitors List
Related Companies and Tools
